Xie F, et al. - Through a cohort study that utilized 2006–2015 Medicare and MarketScan claims for patients with RA in whom treatment with biologic disease-modifying antirheumatic drugs was started following January 1, 2010, researchers evaluated the real-world cardiovascular disease (CVD) risk correlated with tocilizumab, the first anti–interleukin-6 receptor medication approved for the treatment of RA. A total of 88,463 patients with RA were involved. For composite CVD events among Medicare patients, the crude incidence rate (IR) per 1,000 patient-years ranged from 11.8 to 17.3 for etanercept users and infliximab users, respectively. For pooled users, the crude IR of a tumor necrosis factor inhibitor was 15.0. The corresponding adjusted HRs for abatacept, rituximab, etanercept, adalimumab, and infliximab were 1.01, 1.16, 1.10, 1.33, and 1.61, respectively, in comparison with tocilizumab. When MarketScan data were utilized, no statistically important variations in the risk of CVD between tocilizumab and any other biologic could be found. In numerous subgroup analyses and following external adjustment to control for RA disease activity in the subgroup of patients with linked multi-biomarker disease activity test results (n = 4,156), the outcomes were robust. Hence, tocilizumab had a correlation with a CVD risk relative to that for etanercept as well as a number of other biologics employed for the treatment of RA.